吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

休市中 04-17 16:00:00 EDT

137.64

-0.91

-0.66%

盘后137.88

+0.24+0.17%

19:56 EDT

最高139.76	最低136.69	成交量734.59万
今开138.95	昨收138.55	日振幅2.22%
总市值1,708亿	流通市值1,704亿	总股本12.41亿
成交额10.12亿	换手率0.59%	流通股本12.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":137.64,"timestamp":1776456000000,"preClose":138.55,"halted":0,"volume":7345851,"hourTrading":{"tag":"盘后","latestPrice":137.88,"preClose":137.64,"latestTime":"19:56 EDT","volume":1038394,"amount":142924727.8306,"timestamp":1776470207634,"change":0.24,"changeRate":0.001744,"amplitude":0.001744},"delay":0,"changeRate":-0.006568025983399675,"floatShares":1238162880,"shares":1240679623,"eps":6.78,"marketStatus":"休市中","change":-0.91,"latestTime":"04-17 16:00:00 EDT","open":138.95,"high":139.76,"low":136.69,"amount":1012191787.8484501,"amplitude":0.022158,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.78,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1776672000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":696056400000,"exchange":"NASDAQ","adjPreClose":138.55,"dividendRate":0.022958,"preHourTrading":{"tag":"盘前","latestPrice":138.95,"preClose":138.55,"latestTime":"09:29 EDT","volume":9583,"amount":1332209.20651,"timestamp":1776432599999,"change":0.4,"changeRate":0.002887,"amplitude":0.011002},"postHourTrading":{"tag":"盘后","latestPrice":137.88,"preClose":137.64,"latestTime":"19:56 EDT","volume":1038394,"amount":142924727.8306,"timestamp":1776470207634,"change":0.24,"changeRate":0.001744,"amplitude":0.001744},"volumeRatio":1.581582339326038,"impliedVol":0.3319,"impliedVolPercentile":0.548},"requestUrl":"/m/hq/s/GILD/tweets","defaultTab":"tweets","newsList":[{"id":"2628069201","title":"吉利德科学(GILD)获所有必要监管批准 并延长要约收购期限","url":"https://stock-news.laohu8.com/highlight/detail?id=2628069201","media":"金吾财讯","labels":["policyRegulatory","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628069201?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:12","pubTimestamp":1776431546,"startTime":"0","endTime":"0","summary":"金吾财讯 | 吉利德科学公司 周五宣布，其此前宣布收购 Arcellx 的所有必要监管批准均已获得，并且吉利德已延长收购 Arcellx 所有流通普通股的要约收购期限至2026年4月27日。该CVR的触发条件是Arcellx旗下的细胞治疗产品anito-cel在2029年底前全球累计销售额突破60亿美元。截至4月16日，约17.5%的Arcellx股份已参与投标。吉利德今年正通过大规模并购强化其肿瘤学版图。截至发稿，吉利德盘前股价上涨0.5%，报139.24美元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299380","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","SG9999015978.USD","LU2087621335.USD","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","LU1023059063.AUD","LU1430594728.SGD","LU0234570918.USD","LU0114720955.EUR","LU1778281490.HKD","BK4585","LU0823416689.USD","LU0861579265.USD","LU1674673691.USD","LU0965508806.USD","BK4583","LU1934455277.USD","LU0289739699.SGD","LU0109394709.USD","BK4578","LU0882574055.USD","LU0058720904.USD","LU0965509010.AUD","IE00BSNM7G36.USD","LU1037948897.HKD","BK4532","IE00B19Z3B42.SGD","LU1037948541.HKD","LU1934455863.HKD","LU2468319806.SGD","LU1674673428.USD","BK4139","SG9999015952.SGD","BK4550","LU2324357040.USD","IE00B3T34201.USD","LU0889565916.HKD","BK4568","BK4588","BK4566","LU1066053197.SGD","LU1839511570.USD","LU0965509101.SGD","LU1585245621.USD","GILD","LU1934455194.USD","LU2112291526.USD","SG9999015986.USD","IE00BKVL7J92.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137318945","title":"吉利德科学完成收购Arcellx全部监管审批 并延长股权收购要约期限","url":"https://stock-news.laohu8.com/highlight/detail?id=1137318945","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137318945?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:32","pubTimestamp":1776429123,"startTime":"0","endTime":"0","summary":"吉利德科学公司已获得收购生物技术公司Arcellx所需的全数监管批准，同时宣布将股权收购要约的有效期进行延长。此次监管绿灯的全面亮起，标志着这笔重大交易迈过了关键的法律门槛。收购进程的顺利推进，展现了吉利德在拓展细胞治疗产品线方面的战略决心。\n股权收购要约期的延展，为交易最终完成提供了更充裕的操作空间。这一系列进展预示着两家公司在肿瘤免疫治疗领域的整合即将进入实质性阶段。市场密切关注此次收购对吉利德未来业绩带来的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU1066053197.SGD","BK4566","SG9999015952.SGD","IE00BKVL7J92.USD","LU1585245621.USD","BK4585","LU1037948897.HKD","LU1057294990.SGD","IE00B19Z3581.USD","LU0823416689.USD","LU0234570918.USD","LU1037948541.HKD","LU0882574055.USD","BK4578","LU0965508806.USD","LU0965509010.AUD","LU0109394709.USD","LU2089984988.USD","SG9999015986.USD","SG9999015945.SGD","LU1934455863.HKD","SG9999015978.USD","LU0122379950.USD","LU0058720904.USD","IE00BSNM7G36.USD","LU1430594728.SGD","LU1674673428.USD","LU1778281490.HKD","LU0965509283.SGD","LU1839511570.USD","IE00BZ1G4Q59.USD","GILD","LU1934455194.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00B3T34201.USD","BK4588","LU1571399168.USD","LU1934455277.USD","LU2112291526.USD","LU0114720955.EUR","LU0320765992.SGD","LU1023059063.AUD","LU0861579265.USD","LU2087621335.USD","LU2324357040.USD","IE00B19Z3B42.SGD","BK4139","LU1674673691.USD","LU2468319806.SGD","BK4550","BK4583","LU0889565916.HKD","LU0965509101.SGD","LU1061106388.HKD","BK4568","IE0002270589.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130614255","title":"吉利德科学再度出手收购癌症药物合作伙伴——市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1130614255","media":"投资观察","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130614255?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:26","pubTimestamp":1775572014,"startTime":"0","endTime":"0","summary":"吉利德科学公司再度出手收购其癌症药物合作伙伴，该公司已达成协议，将以最高50亿美元的价格收购Tubulis公司。今年二月，吉利德宣布将收购ARCELLX, INC.的全部剩余股份，该公司是吉利德在开发针对多发性骨髓瘤这一血癌的潜在CAR-T细胞疗法方面的合作伙伴，该交易对这家生物技术公司的估值在交易完成时约为78亿美元。\nRBC资本市场的分析师指出，此次收购Tubulis是一项战略上合理的补充性收购，既能满足吉利德肿瘤学产品管线增长的需求，又能确保获得差异化的下一代抗体偶联药物平台能力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509283.SGD","LU1571399168.USD","LU1430594728.SGD","LU1839511570.USD","LU1066053197.SGD","LU1585245621.USD","LU1934455277.USD","LU1057294990.SGD","LU0965508806.USD","LU1934455194.USD","BK4532","SG9999015945.SGD","BK4583","LU0122379950.USD","LU0823416689.USD","BK4139","LU0861579265.USD","LU2324357040.USD","IE00BSNM7G36.USD","LU0965509010.AUD","LU1674673428.USD","ACLX","BK4550","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4585","IE0002270589.USD","LU1023059063.AUD","BK4588","GILD","LU1066051498.USD","LU0114720955.EUR","LU0882574055.USD","LU2112291526.USD","BK4568","LU2089984988.USD","LU0058720904.USD","LU0234570918.USD","IE00B3T34201.USD","LU1037948897.HKD","LU1061106388.HKD","BK4566","IE00BKVL7J92.USD","LU2468319806.SGD","SG9999015986.USD","LU2087621335.USD","LU0320765992.SGD","LU1934455863.HKD","LU1778281490.HKD","SG9999015952.SGD","SG9999015978.USD","LU1674673691.USD","LU0109394709.USD","LU0289739699.SGD","LU1037948541.HKD","LU0965509101.SGD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0889565916.HKD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625303955","title":"50亿美元掷向ADC赛道，吉利德科学(GILD.US)高价收购德国Tubulis","url":"https://stock-news.laohu8.com/highlight/detail?id=2625303955","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625303955?lang=zh_cn&edition=full","pubTime":"2026-04-07 21:15","pubTimestamp":1775567710,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，吉利德科学同意收购德国私营生物技术公司 Tubulis GmbH，交易总价值高达 50 亿美元。吉利德目前已经销售一种名为 Trodelvy 的乳腺癌 ADC 药物。Tubulis 正在针对卵巢癌、肺癌以及其他类型的肿瘤进行药物临床试验。数据显示，卵巢癌市场到 2030 年的价值可能达到 56 亿美元，Tubulis 在该领域有潜力挑战阿斯利和礼来等巨头。这是吉利德今年以来的第三笔重大交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0114720955.EUR","LU1674673691.USD","BK4588","LU0965509283.SGD","LU0289739699.SGD","IE00BSNM7G36.USD","LU1585245621.USD","LU0965508806.USD","LU0965509101.SGD","LU0234570918.USD","BK4532","BK4231","BK4568","LU0823416689.USD","LU1057294990.SGD","LU0320765992.SGD","LU1037948541.HKD","FDAXmain","LU1839511570.USD","SG9999015986.USD","BK4080","LU0122379950.USD","LU0965509010.AUD","LU1934455194.USD","GILD","LU1023059063.AUD","IE0002270589.USD","BK4566","LU2468319806.SGD","BK4578","LU2089984988.USD","SG9999015978.USD","IE00B3T34201.USD","ADC","FDXSmain","IE00BZ1G4Q59.USD","LU2324357040.USD","LU1061106388.HKD","BK4583","LU1934455277.USD","FDXMmain","LU0889565916.HKD","BK4139","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","LU0882574055.USD","LU0861579265.USD","LU2112291526.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109962795","title":"吉利德科学将收购Tubulis，引入潜在同类最佳抗体偶联药物及新一代平台，进一步强化肿瘤产品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1109962795","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109962795?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:31","pubTimestamp":1775565084,"startTime":"0","endTime":"0","summary":"吉利德科学宣布收购Tubulis公司，此举将为公司带来潜在同类最优的抗体偶联药物以及新一代技术平台，从而显著增强其在肿瘤治疗领域的产品管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU1674673428.USD","LU1674673691.USD","BK4588","LU0965509283.SGD","LU0289739699.SGD","IE00B19Z3581.USD","IE00BSNM7G36.USD","LU0965508806.USD","LU1585245621.USD","SG9999015945.SGD","BK4585","LU0965509101.SGD","SG9999015952.SGD","LU1066051498.USD","LU0234570918.USD","BK4532","LU1934455863.HKD","BK4568","LU0823416689.USD","LU1057294990.SGD","LU0320765992.SGD","LU1037948541.HKD","LU1839511570.USD","SG9999015986.USD","LU0122379950.USD","LU0965509010.AUD","LU1934455194.USD","GILD","LU1023059063.AUD","IE0002270589.USD","BK4566","LU2468319806.SGD","BK4578","LU0058720904.USD","LU1430594728.SGD","LU2089984988.USD","LU1778281490.HKD","IE00B3T34201.USD","SG9999015978.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","LU2324357040.USD","LU1061106388.HKD","BK4583","LU1934455277.USD","LU0889565916.HKD","BK4139","LU1571399168.USD","LU2087621335.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","LU1066053197.SGD","LU0882574055.USD","LU1037948897.HKD","LU0861579265.USD","LU2112291526.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111294591","title":"吉利德科学将以31.5亿美元现金预付款收购Tubulis，潜在里程碑金额高达18.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111294591","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111294591?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:19","pubTimestamp":1775564350,"startTime":"0","endTime":"0","summary":"生物制药巨头吉利德科学宣布达成一项重大收购协议，将以31.5亿美元现金作为预付款，收购专注于抗体偶联药物研发的德国生物技术公司Tubulis。根据协议条款，若Tubulis在后续研发中达成特定里程碑，吉利德还将额外支付最高18.5亿美元的资金。此次交易凸显了吉利德科学在肿瘤治疗领域的战略布局。协议设计的里程碑付款机制，既体现了吉利德对Tubulis技术潜力的认可，也显示出其对研发成果的审慎评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673691.USD","LU1023059063.AUD","IE00BSNM7G36.USD","LU0823416689.USD","BK4550","LU1571399168.USD","LU1934455277.USD","LU0289739699.SGD","LU1430594728.SGD","BK4566","LU0861579265.USD","LU0965509010.AUD","LU1061106388.HKD","SG9999015978.USD","LU0122379950.USD","LU2112291526.USD","IE00B19Z3581.USD","LU1037948541.HKD","LU2468319806.SGD","BK4532","LU1066053197.SGD","LU1585245621.USD","LU0965508806.USD","LU0320765992.SGD","LU0109394709.USD","LU1066051498.USD","BK4585","BK4578","GILD","IE00B19Z3B42.SGD","LU1778281490.HKD","LU1037948897.HKD","LU1934455194.USD","LU2089984988.USD","BK4139","LU1934455863.HKD","BK4568","LU0058720904.USD","LU0965509101.SGD","LU0114720955.EUR","IE00B3T34201.USD","IE00BKVL7J92.USD","LU0965509283.SGD","LU0234570918.USD","LU1057294990.SGD","LU2324357040.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","SG9999015945.SGD","LU1674673428.USD","BK4588","BK4583","LU0889565916.HKD","LU1839511570.USD","IE00BZ1G4Q59.USD","LU0882574055.USD","LU2087621335.USD","IE0002270589.USD","SG9999015986.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136489047","title":"吉利德科学将以31.5亿美元现金收购Tubulis全部流通股权，交易基于无现金无债务基础","url":"https://stock-news.laohu8.com/highlight/detail?id=1136489047","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136489047?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:18","pubTimestamp":1775564314,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，将以31.5亿美元的前期现金对价，收购生物技术公司Tubulis的全部流通股权。此次交易将基于无现金、无债务的基础进行，标志着吉利德在拓展肿瘤治疗管线方面的重大战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","LU1585245621.USD","IE00B3T34201.USD","LU1037948541.HKD","BK4568","LU0109394709.USD","LU0965508806.USD","BK4583","LU0114720955.EUR","LU1066051498.USD","SG9999015978.USD","LU0965509010.AUD","LU2089984988.USD","IE00BKVL7J92.USD","BK4585","LU0234570918.USD","LU1571399168.USD","LU1934455277.USD","IE00BSNM7G36.USD","LU0965509101.SGD","BK4550","LU0320765992.SGD","LU1023059063.AUD","LU0965509283.SGD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU1934455863.HKD","GILD","LU1934455194.USD","LU0882574055.USD","LU0058720904.USD","BK4566","LU0823416689.USD","LU1061106388.HKD","LU0289739699.SGD","LU1066053197.SGD","SG9999015952.SGD","LU2324357040.USD","BK4139","IE00B19Z3581.USD","LU1057294990.SGD","SG9999015945.SGD","LU2087621335.USD","LU0122379950.USD","SG9999015986.USD","LU1778281490.HKD","LU0889565916.HKD","LU2112291526.USD","IE00B19Z3B42.SGD","LU1674673691.USD","LU1839511570.USD","LU0861579265.USD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU1037948897.HKD","BK4532","LU1674673428.USD","IE0002270589.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930681","title":"吉利德科学斥资31.5亿美元现金收购德国生物技术公司Tubulis，交易总价值最高可达50亿美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930681","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625930681?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:03","pubTimestamp":1775563412,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BSNM7G36.USD","BK4566","LU0109394709.USD","FDXSmain","BK4568","LU1061106388.HKD","LU0289739699.SGD","LU1066053197.SGD","BK4588","LU1934455277.USD","LU2089984988.USD","LU0122379950.USD","GILD","LU0965509010.AUD","SG9999015945.SGD","LU1037948897.HKD","LU1023059063.AUD","LU1674673691.USD","LU1430594728.SGD","IE00B3T34201.USD","BK4550","SG9999015986.USD","BK4532","LU0823416689.USD","LU0861579265.USD","LU2324357040.USD","LU1778281490.HKD","LU2112291526.USD","LU1037948541.HKD","LU0889565916.HKD","IE00BKVL7J92.USD","LU0965509283.SGD","LU1057294990.SGD","LU0058720904.USD","LU0965509101.SGD","LU0320765992.SGD","SG9999015978.USD","LU0882574055.USD","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","LU1839511570.USD","LU2468319806.SGD","LU1934455863.HKD","LU0965508806.USD","LU1571399168.USD","FDXMmain","IE00B19Z3581.USD","FDAXmain","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125354028","title":"Galapagos与吉利德科学达成具有约束力协议 携手推进自身免疫性疾病领域首创T细胞衔接器项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1125354028","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125354028?lang=zh_cn&edition=full","pubTime":"2026-03-31 13:32","pubTimestamp":1774935153,"startTime":"0","endTime":"0","summary":"Galapagos公司与吉利德科学（Gilead Sciences）近日签署了一项具有约束力的合作协议，双方将共同推进针对自身免疫性疾病的首创T细胞衔接器项目。这一合作标志着两家公司在免疫疗法领域的重要进展，旨在通过创新疗法为自身免疫性疾病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","BK4583","LU0882574055.USD","LU1066051498.USD","IE00B3T34201.USD","LU2324357040.USD","LU2112291526.USD","LU1934455277.USD","LU0861579265.USD","LU0109394709.USD","LU0889565916.HKD","BK4578","LU1674673428.USD","IE00B7SZLL34.SGD","LU0320765992.SGD","BK4588","BK4139","IE00BKVL7J92.USD","SG9999015945.SGD","LU1934455194.USD","SG9999015986.USD","LU2468319806.SGD","BK4585","LU1571399168.USD","LU2089984988.USD","LU1061106388.HKD","LU0289739699.SGD","LU0114720955.EUR","LU0965508806.USD","LU0823416689.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU1066053197.SGD","LU2087621335.USD","LU1057294990.SGD","SG9999015952.SGD","LU1585245621.USD","LU1839511570.USD","BK4566","BK4550","LU0234570918.USD","LU1037948897.HKD","LU1674673691.USD","LU1778281490.HKD","IE00B19Z3B42.SGD","GILD","BK4568","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU0965509283.SGD","LU1023059063.AUD","IE00B19Z3581.USD","BK4532","LU1934455863.HKD","LU0965509101.SGD","LU1037948541.HKD","LU0058720904.USD","LU0122379950.USD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139494294","title":"Galapagos NV拟独立支出5亿美元，其中最高1.5亿美元用于股份回购或股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1139494294","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139494294?lang=zh_cn&edition=full","pubTime":"2026-03-31 13:32","pubTimestamp":1774935140,"startTime":"0","endTime":"0","summary":"生物技术公司Galapagos NV宣布，计划自主调配高达5亿美元资金，用于支持公司战略发展。这一资金安排中，预计最多1.5亿美元将专项用于股份回购计划或向股东派发股息，其余部分将投入研发及业务拓展。此次资金部署彰显了公司强化财务灵活性的决心，同时兼顾股东回报与长期增长需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU1057294990.SGD","LU1037948541.HKD","SG9999015986.USD","LU0122379950.USD","LU0320765992.SGD","SG9999015945.SGD","LU0861579265.USD","LU1430594728.SGD","LU1066051498.USD","IE00B19Z3581.USD","LU1839511570.USD","BK4532","LU0289739699.SGD","IE00BZ1G4Q59.USD","BK4585","LU2112291526.USD","LU1571399168.USD","IE0002270589.USD","LU0234570918.USD","LU1023059063.AUD","IE00BSNM7G36.USD","IE00B3T34201.USD","BK4578","LU1934455863.HKD","BK4588","LU1674673428.USD","LU0882574055.USD","IE00B7SZLL34.SGD","BK4568","LU0109394709.USD","LU0965509101.SGD","LU1934455277.USD","BK4550","LU2468319806.SGD","BK4583","LU1585245621.USD","LU2324357040.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU0965508806.USD","SG9999015952.SGD","SG9999015978.USD","LU1037948897.HKD","LU1778281490.HKD","GILD","LU0114720955.EUR","BK4566","LU1066053197.SGD","LU1934455194.USD","BK4139","LU0965509010.AUD","LU1674673691.USD","LU0889565916.HKD","LU2087621335.USD","LU0058720904.USD","LU0965509283.SGD","LU0823416689.USD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621956096","title":"吉利德拟以最高21.75亿美元收购Ouro Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2621956096","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621956096?lang=zh_cn&edition=full","pubTime":"2026-03-24 23:10","pubTimestamp":1774365049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 吉利德科学宣布，已签署最终协议收购Ouro Medicines，后者一家专注于开发针对自体免疫疾病疗法的私营生物技术公司。吉利德支付16.75亿美元的预付现金对价(需进行惯例调整)，外加最高5亿美元的或有里程碑付款。该交易为吉利德的炎症产品组合增添了OM336(gamgertamig)，这是一种处于临床阶段的BCMAxCD3 T细胞衔接器。在正在进行的1/2期临床研究中，该药物在严重自体免疫疾病(包括自体免疫性溶血性贫血和免疫性血小板减少症)中显示出疗效。OM336已获得快速通道资格和孤儿药资格。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298333","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0823416689.USD","LU1674673428.USD","IE00B7SZLL34.SGD","BK4139","GILD","LU0965509010.AUD","SG9999015945.SGD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1430594728.SGD","LU0109394709.USD","LU1571399168.USD","IE00B3T34201.USD","LU1839511570.USD","LU2468319806.SGD","LU1057294990.SGD","LU1674673691.USD","LU0861579265.USD","SG9999015952.SGD","LU2089984988.USD","LU2087621335.USD","LU0320765992.SGD","SG9999015978.USD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU1585245621.USD","BK4588","BK4566","SG9999015986.USD","LU0122379950.USD","IE00BSNM7G36.USD","LU1934455863.HKD","LU1066051498.USD","IE00B19Z3581.USD","BK4583","LU0882574055.USD","LU1023059063.AUD","LU2112291526.USD","LU0058720904.USD","LU1037948541.HKD","LU1934455194.USD","LU1934455277.USD","LU1061106388.HKD","IE00BKVL7J92.USD","LU0289739699.SGD","LU0965508806.USD","BK4568","LU1066053197.SGD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123197269","title":"吉利德科学保留大中华区以外全球独家商业化权利，将向Galapagos支付销售额20%-23%的特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1123197269","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123197269?lang=zh_cn&edition=full","pubTime":"2026-03-24 06:17","pubTimestamp":1774304236,"startTime":"0","endTime":"0","summary":"根据最新协议条款，生物制药巨头吉利德科学将保留除大中华区以外的全球独家商业化权利。与此同时，该公司承诺将向合作伙伴Galapagos支付相当于净销售额20%至23%的特许权使用费。这一安排凸显了吉利德科学在全球市场战略布局中的精准定位，同时通过阶梯式分成模式强化了双方的利益共享机制。值得注意的是，大中华区的商业化权利将采用独立运作模式，这反映出该地区在市场规模、监管环境等方面具备的特殊性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509283.SGD","LU1571399168.USD","LU1430594728.SGD","LU1839511570.USD","LU1066053197.SGD","LU1585245621.USD","LU1934455277.USD","LU1057294990.SGD","LU0965508806.USD","LU1934455194.USD","BK4532","SG9999015945.SGD","BK4583","LU0122379950.USD","LU0823416689.USD","BK4139","LU0861579265.USD","LU2324357040.USD","IE00BSNM7G36.USD","LU0965509010.AUD","LU1674673428.USD","BK4550","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4585","IE0002270589.USD","LU1023059063.AUD","BK4588","GILD","LU1066051498.USD","LU0114720955.EUR","LU0882574055.USD","LU2112291526.USD","BK4568","LU2089984988.USD","LU0058720904.USD","LU0234570918.USD","IE00B3T34201.USD","LU1037948897.HKD","LU1061106388.HKD","BK4566","IE00BKVL7J92.USD","LU2468319806.SGD","SG9999015986.USD","LU2087621335.USD","LU0320765992.SGD","LU1934455863.HKD","LU1778281490.HKD","SG9999015952.SGD","SG9999015978.USD","LU1674673691.USD","LU0109394709.USD","LU0289739699.SGD","LU1037948541.HKD","LU0965509101.SGD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0889565916.HKD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156422664","title":"吉利德科学将以16.75亿美元现金对价收购Ouro Medicines全部流通股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1156422664","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156422664?lang=zh_cn&edition=full","pubTime":"2026-03-24 06:16","pubTimestamp":1774304173,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，将以总额16.75亿美元的前期现金对价，收购生物技术公司Ouro Medicines的全部流通股权。此次交易将强化吉利德在创新疗法领域的布局，通过整合Ouro Medicines的专有技术平台，加速下一代治疗方案的开发进程。\n该收购案预计将于近期完成，届时Ouro Medicines的研发团队及技术资产将悉数并入吉利德科学的运营体系。市场观察人士指出，此举反映了大型药企通过战略性收购增强核心竞争力的趋势，尤其在基因编辑与细胞治疗等前沿领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU1674673428.USD","LU1674673691.USD","BK4588","LU0965509283.SGD","LU0289739699.SGD","IE00B19Z3581.USD","IE00BSNM7G36.USD","LU0965508806.USD","LU1585245621.USD","SG9999015945.SGD","BK4585","LU0965509101.SGD","SG9999015952.SGD","LU1066051498.USD","LU0234570918.USD","BK4532","LU1934455863.HKD","BK4568","LU0823416689.USD","LU1057294990.SGD","LU0320765992.SGD","LU1037948541.HKD","LU1839511570.USD","SG9999015986.USD","LU0122379950.USD","LU0965509010.AUD","LU1934455194.USD","GILD","LU1023059063.AUD","IE0002270589.USD","BK4566","LU2468319806.SGD","BK4578","LU0058720904.USD","LU1430594728.SGD","LU2089984988.USD","LU1778281490.HKD","IE00B3T34201.USD","SG9999015978.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","LU2324357040.USD","LU1061106388.HKD","BK4583","LU1934455277.USD","LU0889565916.HKD","BK4139","LU1571399168.USD","LU2087621335.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","LU1066053197.SGD","LU0882574055.USD","LU1037948897.HKD","LU0861579265.USD","LU2112291526.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172994317","title":"吉利德科学正与Galapagos就收购的Ouro Medicines资产展开研发合作深入谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=1172994317","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172994317?lang=zh_cn&edition=full","pubTime":"2026-03-24 06:16","pubTimestamp":1774304171,"startTime":"0","endTime":"0","summary":"吉利德科学目前正与Galapagos公司进行深入磋商，双方拟就吉利德收购的Ouro Medicines资产展开潜在的研发合作。此次谈判标志着两家公司在创新药物开发领域的战略协同进入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","BK4585","LU1839511570.USD","LU2324357040.USD","LU0289739699.SGD","SG9999015978.USD","LU0965509101.SGD","BK4550","LU2087621335.USD","LU0122379950.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0965509010.AUD","LU1037948897.HKD","LU1057294990.SGD","LU1066051498.USD","IE00B19Z3B42.SGD","BK4588","LU2112291526.USD","IE00B7SZLL34.SGD","LU0234570918.USD","SG9999015986.USD","BK4578","LU0965509283.SGD","LU2468319806.SGD","SG9999015952.SGD","IE0002270589.USD","BK4532","LU1430594728.SGD","IE00BKVL7J92.USD","BK4583","LU0965508806.USD","LU1585245621.USD","LU1934455194.USD","LU0109394709.USD","BK4139","LU1066053197.SGD","GILD","LU1934455277.USD","LU1674673691.USD","IE00B19Z3581.USD","LU1037948541.HKD","LU0114720955.EUR","LU0823416689.USD","LU0889565916.HKD","LU1023059063.AUD","BK4566","LU0882574055.USD","LU0320765992.SGD","SG9999015945.SGD","IE00B3T34201.USD","IE00BSNM7G36.USD","BK4568","LU0861579265.USD","LU1061106388.HKD","LU1571399168.USD","LU1674673428.USD","LU1934455863.HKD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145865834","title":"吉利德科学将收购Ouro Medicines，推进其首创的T细胞衔接器项目以治疗自身免疫性疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1145865834","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145865834?lang=zh_cn&edition=full","pubTime":"2026-03-24 06:16","pubTimestamp":1774304170,"startTime":"0","endTime":"0","summary":"吉利德科学已达成协议，将收购Ouro Medicines公司，此举旨在加速推进其首创的T细胞衔接器项目，该项目的重点在于开发针对自身免疫性疾病的创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU1066053197.SGD","BK4566","SG9999015952.SGD","IE00BKVL7J92.USD","LU1585245621.USD","BK4585","LU1037948897.HKD","LU1057294990.SGD","IE00B19Z3581.USD","LU0823416689.USD","LU0234570918.USD","LU1037948541.HKD","LU0882574055.USD","BK4578","LU0965508806.USD","LU0965509010.AUD","LU0109394709.USD","LU2089984988.USD","SG9999015986.USD","SG9999015945.SGD","LU1934455863.HKD","SG9999015978.USD","LU0122379950.USD","LU0058720904.USD","IE00BSNM7G36.USD","LU1430594728.SGD","LU1674673428.USD","LU1778281490.HKD","LU0965509283.SGD","LU1839511570.USD","IE00BZ1G4Q59.USD","GILD","LU1934455194.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00B3T34201.USD","BK4588","LU1571399168.USD","LU1934455277.USD","LU2112291526.USD","LU0114720955.EUR","LU0320765992.SGD","LU1023059063.AUD","LU0861579265.USD","LU2087621335.USD","LU2324357040.USD","IE00B19Z3B42.SGD","BK4139","LU1674673691.USD","LU2468319806.SGD","BK4550","BK4583","LU0889565916.HKD","LU0965509101.SGD","LU1061106388.HKD","BK4568","IE0002270589.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175690757","title":"吉利德科学与Ouro Medicines谈判进入后期阶段 交易有望近日公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1175690757","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175690757?lang=zh_cn&edition=full","pubTime":"2026-03-24 00:37","pubTimestamp":1774283835,"startTime":"0","endTime":"0","summary":"据知情人士透露，生物制药巨头吉利德科学与生物技术公司Ouro Medicines的并购谈判已进入关键阶段。双方正就最终条款进行磋商，若谈判顺利，这项备受业界关注的交易可能在未来数日内正式对外公告。此次潜在收购将强化吉利德在创新疗法领域的战略布局。市场观察人士指出，此举延续了吉利德近年来通过并购加速创新的战略路径。随着谈判进入收官阶段，两家公司股价近日均呈现波动上行态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","BK4583","LU0882574055.USD","LU1066051498.USD","IE00B3T34201.USD","LU2324357040.USD","LU2112291526.USD","LU1934455277.USD","LU0861579265.USD","LU0109394709.USD","LU0889565916.HKD","BK4578","LU1674673428.USD","IE00B7SZLL34.SGD","LU0320765992.SGD","BK4588","BK4139","IE00BKVL7J92.USD","SG9999015945.SGD","LU1934455194.USD","SG9999015986.USD","LU2468319806.SGD","BK4585","LU1571399168.USD","LU2089984988.USD","LU1061106388.HKD","LU0289739699.SGD","LU0114720955.EUR","LU0965508806.USD","LU0823416689.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU1066053197.SGD","LU2087621335.USD","LU1057294990.SGD","SG9999015952.SGD","LU1585245621.USD","LU1839511570.USD","BK4566","BK4550","LU0234570918.USD","LU1037948897.HKD","LU1674673691.USD","LU1778281490.HKD","IE00B19Z3B42.SGD","GILD","BK4568","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU0965509283.SGD","LU1023059063.AUD","IE00B19Z3581.USD","BK4532","LU1934455863.HKD","LU0965509101.SGD","LU1037948541.HKD","LU0058720904.USD","LU0122379950.USD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102792638","title":"吉利德科学将以约15亿美元现金预付款收购Ouro，若临床试验达标还将额外支付至少5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102792638","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102792638?lang=zh_cn&edition=full","pubTime":"2026-03-24 00:37","pubTimestamp":1774283833,"startTime":"0","endTime":"0","summary":"吉利德科学将向私人控股的Ouro公司投资者支付约15亿美元现金作为预付款。此外，若达成特定临床试验里程碑，吉利德科学还将额外支付至少5亿美元资金。该交易结构凸显了生物医药行业对创新疗法的高估值趋势，资金支付与研发进展深度绑定的模式也成为当前并购交易的新特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965508806.USD","LU1674673691.USD","LU0122379950.USD","IE00B3T34201.USD","LU0114720955.EUR","BK4588","LU0965509101.SGD","LU1934455194.USD","BK4578","LU1934455863.HKD","SG9999015986.USD","LU2112291526.USD","IE00BKVL7J92.USD","SG9999015945.SGD","LU2089984988.USD","BK4583","LU0823416689.USD","LU0965509010.AUD","LU0289739699.SGD","LU0965509283.SGD","LU1061106388.HKD","LU1066053197.SGD","LU1571399168.USD","LU1674673428.USD","LU1023059063.AUD","LU1839511570.USD","IE0002270589.USD","LU0109394709.USD","SG9999015978.USD","BK4566","LU1037948897.HKD","LU1934455277.USD","LU0320765992.SGD","BK4139","IE00B7SZLL34.SGD","GILD","LU0234570918.USD","LU1778281490.HKD","IE00B19Z3581.USD","BK4532","LU1037948541.HKD","IE00BZ1G4Q59.USD","SG9999015952.SGD","LU1585245621.USD","LU2087621335.USD","IE00B19Z3B42.SGD","LU2324357040.USD","LU1057294990.SGD","BK4568","IE00BSNM7G36.USD","LU0861579265.USD","LU0058720904.USD","LU1066051498.USD","LU0882574055.USD","LU0889565916.HKD","LU2468319806.SGD","LU1430594728.SGD","BK4585","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620225813","title":"吉利德科学(GILD.US)CD19/CD20 CAR-T细胞疗法启动III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225813","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620225813?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:12","pubTimestamp":1773925932,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月18日，美国临床试验收录网站显示，吉利德科学旗下公司Kite Pharma启动了KITE-753的首个III期临床试验。KITE-753是一款靶向CD19和CD20的双顺反子自体CAR-T细胞疗法。研究的主要终点是第6个月实现完全缓解的患者比例和36个月内的无事件生存期。结果显示，剂量3队列，在14例未接受过CAR-T细胞疗法治疗的患者中，11例实现CR，CR率为79%;总人群，在20例未接受过CAR-T细胞疗法治疗的患者中，14例实现CR，CR率为70%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0882574055.USD","LU1571399168.USD","LU0109394709.USD","BK4134","LU1934455863.HKD","LU1061106388.HKD","BK4583","CAR","LU0823416689.USD","IE00BKVL7J92.USD","BK4568","LU0289739699.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1037948541.HKD","LU1037948897.HKD","LU1839511570.USD","LU2112291526.USD","BK4022","LU0965509101.SGD","IE0002270589.USD","SG9999015986.USD","SG9999015978.USD","GILD","BK4532","LU0122379950.USD","LU0965509283.SGD","LU1674673428.USD","LU2089984988.USD","BK4139","IE00BZ1G4Q59.USD","LU1674673691.USD","LU2087621335.USD","LU0889565916.HKD","BK4588","LU1066051498.USD","SG9999015952.SGD","LU0058720904.USD","LU1430594728.SGD","LU0114720955.EUR","III","LU0861579265.USD","LU1066053197.SGD","SG9999015945.SGD","LU0965508806.USD","LU0965509010.AUD","LU1585245621.USD","LU0234570918.USD","IE00B3T34201.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618188727","title":"华尔街机构的钱都去哪了？美银最新报告：全在AI里，Palantir(PLTR.US)、博通(AVGO.US)排队吸金","url":"https://stock-news.laohu8.com/highlight/detail?id=2618188727","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618188727?lang=zh_cn&edition=full","pubTime":"2026-03-12 14:43","pubTimestamp":1773297797,"startTime":"0","endTime":"0","summary":"博通、Arista Networks、安费诺等AI产业链及半导体关联企业，机构持股同样大幅增长，凸显机构资金正全面转向AI基础设施与数据技术领域。Meta、奈飞等大型通信服务企业，同样获得机构新增持仓。前五名其余个股为西部数据、博通、GE Vernova，均为“持有”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0215105999.USD","LU1935042215.USD","LU1267930730.SGD","LU1803068979.SGD","LU2896262040.SGD","PLTR","PLTG","LU2456880835.USD","LU0109392836.USD","IE0001KFT4U8.USD","SG9999002224.SGD","LU0348723411.USD","BK4515","LU1917777945.USD","IE00BGHQF631.EUR","LU1868837300.USD","LU2264538146.SGD","LU0203347892.USD","IE00BVYPNW00.USD","LU0187121727.USD","LU1153585028.USD","LU0289739343.SGD","LU0320765646.SGD","LU0784385170.HKD","LU0238689110.USD","LU1551013425.SGD","LU0979878070.USD","LU2237443465.HKD","LU0787776722.HKD","LU2746668974.SGD","PLTW","LU0965508806.USD","LU0949170426.SGD","LU1064131342.USD","LU1934455863.HKD","LU0109391861.USD","SG9999004303.SGD","LU1868836757.USD","LU2168564495.EUR","IE00BVYPNQ40.USD","LU2023250843.SGD","LU0256863902.USD","LU1935043023.USD","LU2764263039.SGD","IE00BK4W5L77.USD","IE00B19Z9Z06.USD","LU2756315318.SGD","IE00B775H168.HKD","LU0274383776.USD","IE00BK4W5M84.HKD","LU0316494557.USD","LU0466842654.USD","LU0868494708.USD","LU1674673428.USD","LU1674673691.USD","LU0124676726.USD","LU2360032135.SGD","IE00B3S45H60.SGD","LU0689472784.USD","BK4581","LU2250418816.HKD","IE0034235188.USD","SGXZ81514606.USD","LU0106261372.USD","IE00BMCWC346.EUR","LU1778281490.HKD","LU2403377893.USD","LU2211814178.USD","IE00BGHQDM52.EUR","LU1951198990.SGD","LU0354030438.USD","IE00B5949003.HKD","LU2860962120.EUR","LU0154236417.USD","LU2265009873.SGD","LU2360108059.USD","LU2361044949.HKD","IE00BQXX3D17.EUR","LU1242518857.USD","IE00B775SV38.USD","LU1623119135.USD","LU1934455194.USD","LU0823434740.USD","LU1244550577.SGD","IE00BFSS7M15.SGD","LU0057025933.USD","LU0726765562.USD","LU1951200564.SGD","LU2063271972.USD","LU2272731865.HKD","LU2471134796.USD","IE00BN29S564.USD","LU0553294199.USD","LU1989764748.USD","LU2471134952.CNY","LU1670710661.SGD","IE00BJJMRX11.SGD","IE00B19Z9P08.USD","BK4585","LU0965509101.SGD","IE00B42XCP33.USD","LU0157215616.USD","IE00BLSP4239.USD","LU1548497426.USD","LU2092937221.SGD","LU2106854487.HKD","LU2360106780.USD","LU0210528500.USD","SG9999001440.SGD","LU0965509010.AUD","LU1003077747.HKD","BK4612","IE00BMPRXN33.USD","BK4533","IE00BMPRXR70.SGD","LU2463028550.USD","LU0683600562.USD","LU0820562030.AUD","LU0672654240.SGD","LU0823434583.USD","LU0708995401.HKD","AVGO","LU2471134879.HKD","LU0912757837.SGD","LU0289961442.SGD","LU2347655073.USD","LU2125154778.USD","LU2322448791.USD","LU1316542783.SGD","LU0048584097.USD","LU1232071149.USD","LU1974910355.USD","ANET","LU1732800096.USD","LU1670711040.USD","AVGU","LU1323610961.USD","LU0957791311.USD","IE00BJJMRY28.SGD","LU1814569148.SGD","IE00BYV24P56.USD","LU2213496289.HKD","LU0738911758.USD","BK4566","IE00BJTD4V19.USD","IE00BDGV0183.EUR","LU2430703251.USD","IE00B894F039.SGD","LU0985320562.USD","LU0820561818.USD","LU2430703178.SGD","GEV","LU0795875086.SGD","LU2461242641.AUD","LU1642822529.SGD","LU1366192091.USD","SG9999001424.SGD","LU2237438978.USD","LU2471134523.USD","LU2168564149.EUR","LU0234570918.USD","LU2750360997.AUD","LU1935042991.SGD","LU2750360641.GBP","LU2764263203.CNY","IE00B4JS1V06.HKD","IE00B1BXHZ80.USD","LU0417517546.SGD","LU1244550221.USD","LU2247934214.USD","LU2041044095.USD","BK4551","IE00BKVL7J92.USD","LU1670711123.USD","LU0345769128.USD","LU0353189763.USD","LU2931357623.SGD","LU2023250504.SGD","LU1732799900.SGD","BK4547","PTIR","IE00BJTD4N35.SGD","LU1670710588.SGD","LU0943347566.SGD","LU2764262908.HKD","AVL","LU0786609619.USD","LU1162221912.USD","LU1691799644.USD","LU2089985449.USD","LU2720916845.USD","LU1035775433.USD","IE0034235303.USD","LU2023250330.USD","LU0689626769.HKD","LU1989764664.SGD","LU2242649171.HKD","LU0056508442.USD","LU2211815571.USD","LU0203345920.USD","LU1244550494.USD","LU2237443549.SGD","LU0661504455.SGD","LU0472753341.HKD","LU1720051017.SGD","BK4512","LU0061475181.USD","LU0225283273.USD","LU0069063385.USD","LU1923623000.USD","LU2168563687.JPY","LU1551013342.USD","IE00BJLML261.HKD","BK4598","LU2462157665.USD","PLTI","PLYY","LU0820561909.HKD","LU1815336760.USD","LU1037948897.HKD","LU0965509283.SGD","LU2347655156.SGD","IE00BQXX3C00.GBP","SG9999015945.SGD","LU0320765059.SGD","LU1992135399.USD","LU0345770993.USD","LU2505996681.GBP","LU1127390331.HKD","LU2065170008.USD","LU2357305700.SGD","LU0345768740.USD","BK4575","LU0011850046.USD","IE0009356076.USD","LU0784385840.USD","LU0345770308.USD","AVS","LU2244417387.USD","LU0053666078.USD","LU2065171402.SGD","BK4588","IE00BQXX3F31.USD","LU0079474960.USD","LU0256863811.USD","LU1804176565.USD","LU0345769631.USD","LU0203201768.USD","LU1914381329.SGD","LU2237443978.SGD","LU2133065610.SGD","LU2237957811.SGD","IE00BKPKM429.USD","IE00BFSS8Q28.SGD","LU2361045086.USD","LU2065171311.SGD","LU0096364046.USD","LU0210536198.USD","BK4023","LU0210533765.USD","LU0354030511.USD","LU1934455277.USD","PLTD","LU2417539215.USD","APH","LU2065169927.USD","PLTU","BK4141","LU0964807845.USD","LU0861579265.USD","LU0942090050.USD","LU2108987350.USD","IE00B3PB1722.GBP","LU2746668461.USD","IE00BLSP4452.SGD","LU2361044865.SGD","LU2286300806.USD","LU0642271901.SGD","LU2279689827.SGD","LU2420271590.USD","IE00BMPRXQ63.HKD","SGXZ23171101.USD","SG9999002232.USD","LU0444973449.USD","LU1935042488.USD","SGXZ99366536.SGD","LU0640476718.USD","LU0353189680.USD","SG9999015978.USD","LU0170899867.USD","LU0444971666.USD","LU2237443895.HKD","LU1868837136.USD","LU0868494617.USD","LU2125154935.USD","SG9999011175.SGD","LU2487616109.SGD","IE00BVYPNV92.GBP","LU2298321311.HKD","LU2543165471.USD","LU1861558580.USD","LU2602419157.SGD","LU0006306889.USD","LU2054465674.USD","LU2087625088.SGD","LU2236285917.USD","IE00BBT3K403.USD","LU1301847155.USD","LU0234572021.USD","LU1868836914.USD","LU0323591593.USD","LU0719512351.SGD","LU2505996509.AUD","SG9999003800.SGD","LU2168564065.EUR","IE00BZ1G4Q59.USD","LU1852331112.SGD","LU1280957306.USD","LU2430703095.HKD","AVGG","LU2473716301.USD","AVGX","PLOO","LU0784384876.USD","LU1815333072.USD","IE00BN8TJ469.HKD","BK4613","GILD","LU0127658192.USD","LU0889565833.HKD","LU2458330169.SGD","LU0795875169.SGD","LU2237443382.USD","IE0005OL40V9.USD","LU1629891620.HKD","LU1988902786.USD","LU1712237335.SGD","LU1242518931.SGD","LU0198837287.USD","LU0545039389.USD","LU0061474960.USD","LU2458330243.SGD","LU0784383803.USD","SG9999015952.SGD","LU1861559042.SGD","LU0080751232.USD","LU2237957902.USD","LU0476273544.USD","BK4543","LU2083900584.USD","SG9999015986.USD","IE00BWXC8680.SGD","SGXZ51526630.SGD","LU2592432038.USD","LU0251132253.USD","LU2355687059.USD","LU2272731782.SGD","IE00BKDWB100.SGD","LU0082616367.USD","LU0097036916.USD","LU2756315664.SGD","PLTZ","LU0345768153.USD","LU1670627923.USD","LU1992135472.HKD","LU0957808578.USD","LU0081259029.USD","LU1720051108.HKD","LU0949170772.SGD","BK4605","PLTA","LU2237443622.USD","LU2322448957.HKD","IE00B1XK9C88.USD","LU0203202063.USD","LU1145028129.USD","IE0004445239.USD","LU1037948541.HKD","IE00B7KXQ091.USD","IE0004445015.USD","LU1935043536.SGD","LU1366333091.USD","LU1868836591.USD","PLTY","IE00BVYPNP33.GBP","LU2242650005.HKD","LU2272731600.USD","LU1069344957.HKD","LU1670628061.USD","BK4554","LU0096362180.USD","PLT","LU2168564222.USD","LU0511384066.AUD","IE00BZ9MQY76.HKD","AVGW"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2617652713","title":"吉利德科学盘中异动 早盘股价大跌3.00%报143.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617652713","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617652713?lang=zh_cn&edition=full","pubTime":"2026-03-06 00:14","pubTimestamp":1772727296,"startTime":"0","endTime":"0","summary":"北京时间2026年03月06日00时14分，吉利德科学股票出现异动，股价急速下跌3.00%。截至发稿，该股报143.78美元/股，成交量120.246万股，换手率0.10%，振幅1.99%。吉利德科学股票所在的制药行业中，整体跌幅为2.25%。吉利德科学公司简介：吉利德科学开发和销售治疗和预防危及生命的传染病的疗法，其投资组合的核心集中在艾滋病毒和乙型肝炎和丙型肝炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306001457a6a76b37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306001457a6a76b37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1066051498.USD","BK4588","BK4583","LU1037948897.HKD","LU1430594728.SGD","BK4532","LU0234570918.USD","LU0289739699.SGD","LU1061106388.HKD","BK4139","IE00B7SZLL34.SGD","LU1057294990.SGD","LU0823416689.USD","LU1023059063.AUD","LU0861579265.USD","BK4585","LU0965508806.USD","LU2324357040.USD","LU2087621335.USD","BK4568","GILD","IE00BKVL7J92.USD","IE00B3T34201.USD","LU1674673428.USD","BK4578","LU0882574055.USD","LU1778281490.HKD","LU1037948541.HKD","LU1674673691.USD","SG9999015952.SGD","IE00BSNM7G36.USD","SG9999015945.SGD","LU0965509101.SGD","IE0002270589.USD","LU0320765992.SGD","SG9999015986.USD","SG9999015978.USD","LU2112291526.USD","LU0114720955.EUR","LU0122379950.USD","LU1934455194.USD","BK4550","LU1585245621.USD","LU0109394709.USD","LU1934455863.HKD","IE00B19Z3B42.SGD","LU2468319806.SGD","IE00BZ1G4Q59.USD","LU1839511570.USD","LU0965509010.AUD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0258},{"period":"3month","weight":0.1019},{"period":"6month","weight":0.1208},{"period":"1year","weight":0.3166},{"period":"ytd","weight":0.1214}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.0689},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0414}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.044916},{"month":2,"riseRate":0.428571,"avgChangeRate":0.008369},{"month":3,"riseRate":0.514286,"avgChangeRate":-0.011268},{"month":4,"riseRate":0.514286,"avgChangeRate":0.011277},{"month":5,"riseRate":0.558824,"avgChangeRate":0.0204},{"month":6,"riseRate":0.647059,"avgChangeRate":0.025673},{"month":7,"riseRate":0.558824,"avgChangeRate":0.01609},{"month":8,"riseRate":0.558824,"avgChangeRate":0.033158},{"month":9,"riseRate":0.558824,"avgChangeRate":0.031157},{"month":10,"riseRate":0.529412,"avgChangeRate":0.003173},{"month":11,"riseRate":0.647059,"avgChangeRate":0.039736},{"month":12,"riseRate":0.382353,"avgChangeRate":0.010114}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}